Latest filings (excl ownership)
8-K
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
29 Mar 24
10-K
2023 FY
Annual report
29 Mar 24
8-K
Submission of Matters to a Vote of Security Holders
11 Dec 23
8-K
Regulation FD Disclosure
7 Dec 23
8-K/A
Results of Operations and Financial Condition
13 Nov 23
8-K
Results of Operations and Financial Condition
13 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
ARS
2022 FY
Annual report to shareholders
6 Oct 23
DEFA14A
Additional proxy soliciting materials
6 Oct 23
DEF 14A
Definitive proxy
6 Oct 23
8-K
Results of Operations and Financial Condition
14 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Results of Operations and Financial Condition
15 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
EFFECT
Notice of effectiveness
25 Apr 23
CORRESP
Correspondence with SEC
20 Apr 23
UPLOAD
Letter from SEC
19 Apr 23
S-3
Shelf registration
14 Apr 23
S-8
Registration of securities for employees
30 Mar 23
8-K
Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update
30 Mar 23
10-K
2022 FY
Annual report
30 Mar 23
8-K
Other Events
2 Mar 23
8-K
Other Events
5 Jan 23
8-K
Submission of Matters to a Vote of Security Holders
6 Dec 22
8-K
Regulation FD Disclosure
1 Dec 22
8-K
Results of Operations and Financial Condition
14 Nov 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
DEFA14A
Additional proxy soliciting materials
17 Oct 22
DEF 14A
Definitive proxy
17 Oct 22
8-K
Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer
12 Oct 22
PRE 14A
Preliminary proxy
6 Oct 22
8-K
Other Events
6 Oct 22
8-K
Results of Operations and Financial Condition
15 Aug 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
8-K
Galectin Therapeutics Announces $60 Million Credit Line
26 Jul 22
8-K
Results of Operations and Financial Condition
16 May 22
10-Q
2022 Q1
Quarterly report
16 May 22
8-K
Other Events
14 Apr 22
8-K
Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update
31 Mar 22
10-K
2021 FY
Annual report
31 Mar 22
Latest ownership filings
4
JOEL LEWIS
25 Apr 24
5
JAMES C CZIRR
25 Apr 24
4
JAMES C CZIRR
25 Apr 24
4
KEVIN D FREEMAN
22 Apr 24
4
KEVIN D FREEMAN
9 Apr 24
4
JOEL LEWIS
4 Mar 24
3
BENJAMIN CARSON SR
16 Feb 24
4
Richard A. Jr. Zordani
7 Feb 24
4
Richard E Uihlein
7 Feb 24
4
Elissa J. Schwartz
7 Feb 24
4
Marc Rubin
7 Feb 24
4
GILBERT S OMENN
7 Feb 24
4
JOEL LEWIS
7 Feb 24
4
KEVIN D FREEMAN
7 Feb 24
4
KARY ELDRED
7 Feb 24
4
BENJAMIN CARSON SR
7 Feb 24
4
JACK W CALLICUTT
7 Feb 24
4
Pol F Boudes
7 Feb 24
4
GILBERT F AMELIO
7 Feb 24
4
KARY ELDRED
16 Jan 24
4
JOEL LEWIS
2 Jan 24
4
JOEL LEWIS
18 Dec 23
5
JAMES C CZIRR
1 Dec 23
SC 13D/A
10X Fund, L.P.
1 Dec 23
4
JOEL LEWIS
1 Dec 23
4
JOEL LEWIS
15 Nov 23
4
JOEL LEWIS
31 Oct 23
4/A
JOEL LEWIS
16 Oct 23
4
JOEL LEWIS
16 Oct 23
4
JOEL LEWIS
2 Oct 23
4
Richard E Uihlein
27 Sep 23
4
JOEL LEWIS
18 Sep 23
144
Notice of proposed sale of securities
11 Sep 23
4
JOEL LEWIS
1 Sep 23
4
JOEL LEWIS
15 Aug 23
4
JOEL LEWIS
31 Jul 23
4
KARY ELDRED
20 Jul 23
4
JOEL LEWIS
17 Jul 23
4
JOEL LEWIS
3 Jul 23
4
JOEL LEWIS
16 Jun 23